SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

   Microcap & Penny StocksMicrocap Kitchen Canadian Stocks


Previous 10 Next 10 
To: 31Floors who wrote (49055)8/25/2019 5:34:17 PM
From: 31Floors
   of 49210
 
The website is going to be updated soon. This link is the one you should be using to research news. It is a complete listing of NRs

newswire.ca

Share RecommendKeepReplyMark as Last Read


From: 31Floors8/28/2019 11:15:05 AM
   of 49210
 
Ipa lost $3.7 m after 3Q but $1.2 m are one time costs and $290k is s profit share with U protein shareholders as part of the purchase agreement. This profit sharing arrangement will end in 2020. One time costs were for integrating Europe into what are now global operations; tied together with a new ERP / CRM system. If IPA can execute the plan, look out.

Share RecommendKeepReplyMark as Last Read


From: 31Floors8/29/2019 12:54:39 AM
   of 49210
 
IPA reported a big $7.6 million loss; an adjusted EBITDA loss of $4.4 million (EBITDA & Accretion expense of $904k.)

ADJUSTED EBITDA:
NET LOSS (7,617)
INTEREST EXPENSE 413
TAXES 5
AMORTIZATION 1,875
ACCRETION 904
(4,420)


Note that $1.312 million of this adj EBITDA loss of $4.4 million were ONE TIME costs incurred to bring on global services (European operations) and the critical CRM/ ERP system which will soon be going online.

Q4 revenues disappointed so rumours of significant new customers (who demand confidentiality) didn't have much of an impact - yet - it would appear. Also impacting was that they did a lot of write offs in cost of sales in Q4 with gross margins of 22% for the quarter bringing down the total year margins to 48%.

So its disappointing but well worth remembering that B cell select (tm) is available at IPA globally now and ONE job can run the customer several hundred thousand USD. As well, and not that this would apply to every job I 'm sure but an antibody discovery that the customer wants to work with to take to a stage 1 clinical trial would entail additional work by IPA. If each step is successful, the all in sales gets you looking at closer to US$2m range plus or minus. That;s one b cell project and we can run around 100 or more annually I believe?? And all this B cell work is high margin stuff. So

Let's not forget the role, also, of the full service B Cell offering that is IPA is and Dr. Bath's comment that they had been hired by one firm for example to replace all of that firm's 26 existing CROs (contractors - like IPA is a contractor). You can bet that some of that will start kicking in in the new fiscal. So in the rush to dump IPA based on Q4, some opportune investors are going to get in quite cheaply and be able to ride the wave from there.

And if being a contractor is not exciting then there is TALEM the new sub which gives IPA their platform for owning antibody discoveries; collaboration w/ pharmaceutical partners; sales and royalties from potential new drugs or other applications. They have been doing research globally and that's in the annual costs, too.

stockwatch.com

immunoprecise.com



Not advice, it always takes longer to do and they have to do it. Hoping for more traction in Q1 and Q2. Please do your own DD!

Share RecommendKeepReplyMark as Last ReadRead Replies (2)


From: kidl8/29/2019 1:30:52 PM
   of 49210
 
ENW ... Since I have been commenting on ENW for a long time ...

Today’s reaction to Q3 results proves that dumb retail hasn’t yet completely bailed out. Yes, there is and should be concern about excessive share based compensation BUT there is so much good stuff in the MD&A which imho renders current sellers utter idiots.

Share RecommendKeepReplyMark as Last Read


To: 31Floors who wrote (49058)8/29/2019 1:33:25 PM
From: Claude Cormier
   of 49210
 
I intend to load up at the next low which I believe will be a major buying opportunity.

Share RecommendKeepReplyMark as Last ReadRead Replies (3)


To: Claude Cormier who wrote (49060)8/29/2019 1:57:40 PM
From: 31Floors
   of 49210
 
Good luck Claude.

Share RecommendKeepReplyMark as Last Read


To: Claude Cormier who wrote (49060)8/30/2019 7:05:42 AM
From: Frankly Speaking
   of 49210
 
Can anyone suggest a good entry point for ENW?

Share RecommendKeepReplyMark as Last Read


To: 31Floors who wrote (49058)9/1/2019 12:40:41 PM
From: 31Floors
   of 49210
 
It's a bit ironic that the only NR IPA has issued about signing a large pharmaceutical co is this one, a top 15 for its hibridoma platform and not B cell Select(tm) or DeepDisplay (tm).

It's the B cell Select platform that is the most prominent platform that's caught the attention of multiple majors (direct view into B cells to show much greater depth allowing the selection of many more candidates vs traditional B cell discovery methods.

Anyway, this agreement from last October serves as a hint of how well rounded IPA is as a full service Antibody discovery CRO.

newswire.ca

en.m.wikipedia.org

*************

It's totally expected to see IPA sell off into the mid .50s after the disappointing Q4 Numbers. More discerning or perhaps less pained shareholders may have kept in mind that the quarter just reported ended one month PRIOR to this NR. Fingers crossed to see some revenues from the following programs recognized in Q1 ending July 31 and Q2. Let's break this $3m /quarter glass ceiling!

newswire.ca

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: 31Floors who wrote (49063)9/5/2019 9:35:50 AM
From: 31Floors
   of 49210
 
WTF??

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: 31Floors who wrote (49064)9/5/2019 9:53:45 AM
From: WorthaDeeperLook
   of 49210
 
What's up 31Floors?

Share RecommendKeepReplyMark as Last ReadRead Replies (1)
Previous 10 Next 10